Literature DB >> 20692805

Surgical difficulties encountered with use of modular endoprosthesis for limb preserving salvage of failed allograft reconstruction after malignant tumor resection.

Leon S S Foo1, Jendrik Hardes, Marcel Henrichs, Helmut Ahrens, Georg Gosheger, Arne Streitbürger.   

Abstract

We reviewed outcomes and discussed surgical difficulties encountered in 10 patients who had modular endoprosthesis for limb preserving salvage of failed allograft reconstruction after malignant tumor resection. Mean allograft survival time before failure was 127.4 months (range, 14-264 months). Mean length of follow-up since endoprosthesis revision surgery was 62.8 months (range, 16-132 months). There was one endoprosthesis failure, resulting in a mean endoprosthesis survival time of 56.9 months (range, 16-132). Complications included arterial laceration, nerve injury, periprosthetic crack fracture, aseptic loosening, and infection. Modular endoprosthesis remain a viable option that should be considered in any limb preserving salvage of failed allograft reconstructions. However, altered anatomy, poor/short remnant host bone, periprosthetic fractures, inadequate soft tissue coverage and infection remain important difficulties encountered.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20692805     DOI: 10.1016/j.arth.2010.06.011

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  9 in total

Review 1.  [Osteosarcoma and chondrosarcoma of the pelvis and lower extremities].

Authors:  W K Guder; J Hardes; G Gosheger; M Nottrott; A Streitbürger
Journal:  Chirurg       Date:  2015-10       Impact factor: 0.955

2.  Osteogenic activity of silver-loaded coral hydroxyapatite and its investigation in vivo.

Authors:  Yu Zhang; Qing-Shui Yin; Chu-Song Zhou; Hong Xia; Ying Zhang; Yan-Peng Jiao
Journal:  J Mater Sci Mater Med       Date:  2014-01-14       Impact factor: 3.896

3.  [Bone defect reconstruction in bone sarcoma surgery: tumour endoprosthesis versus biological reconstruction].

Authors:  A Streitbürger; G Gosheger; R Dieckmann; M Nottrott; H Ahrens; J Hardes
Journal:  Unfallchirurg       Date:  2014-07       Impact factor: 1.000

4.  Intermittent internal fixation with a locking plate to preserve epiphyseal growth function during limb-salvage surgery in a child with osteosarcoma of the distal femur: a case report.

Authors:  Jiong Mei; Ming Ni; Guang-Yao Jia; Yan-Xi Chen; Xiao-Zhong Zhu
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

5.  Periprosthetic joint infections in modular endoprostheses of the lower extremities: a retrospective observational study in 101 patients.

Authors:  Dirk Zajonz; Almut Zieme; Torsten Prietzel; Michael Moche; Solveig Tiepoldt; Andreas Roth; Christoph Josten; Georg Freiherr von Salis-Soglio; Christoph-E Heyde; Mohamed Ghanem
Journal:  Patient Saf Surg       Date:  2016-02-09

6.  Surgical management of appendicular skeletal metastases in thyroid carcinoma.

Authors:  Robert L Satcher; Patrick Lin; Nursat Harun; Lei Feng; Bryan S Moon; Valerae O Lewis
Journal:  Int J Surg Oncol       Date:  2012-12-12

7.  Silver-coated modular Megaendoprostheses in salvage revision arthroplasty after periimplant infection with extensive bone loss - a pilot study of 34 patients.

Authors:  Dirk Zajonz; Undine Birke; Mohamed Ghanem; Torsten Prietzel; Christoph Josten; Andreas Roth; Johannes K M Fakler
Journal:  BMC Musculoskelet Disord       Date:  2017-09-02       Impact factor: 2.362

8.  What Are the Long-term Results of MUTARS® Modular Endoprostheses for Reconstruction of Tumor Resection of the Distal Femur and Proximal Tibia?

Authors:  Michaël P A Bus; Michiel A J van de Sande; Marta Fiocco; Gerard R Schaap; Jos A M Bramer; P D Sander Dijkstra
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

9.  Revision surgeries for tumor endoprostheses around the knee joint: a mid-long-term follow-up of 20 cases.

Authors:  Pengfei Zan; Hongsheng Wang; Zhengdong Cai; Jiakang Shen; Wei Sun
Journal:  World J Surg Oncol       Date:  2022-03-10       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.